The United States pharmaceutical giant, reporting surging first-quarter profits based on a big jump in revenues from its Covid-19 vaccine, said its Paxlovid treatment for the virus would be a valuable means for governments to limit the severity of outbreaks as they ease social distancing and masking rules.
"People are tired of the repeated booster, so it is extremely important to come to a vaccine that could be a yearly vaccine," Dr Bourla told analysts on a conference call, adding that while the company has made progress on this front,"it's not technically easy to achieve." But the company confirmed its full-year revenue forecast of about US$100 billion, which is an approximately 23 per cent increase on the 2021 level. More than half the revenues are expected to come from the Covid-19 vaccine and therapeutic.
The company expects to produce 120 million courses of the Paxlovid oral pills in 2022, with distribution programs scaling up in the United States and other markets. "What we're also seeing is that we don't have any inventory on hand," Ms Hwang said."Every dose that we produce is being shipped out."
Source: News Formal (newsformal.com)